Global Longlife Hospital And Research Ltd vs Gujarat Kidney Super Speciality Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 24, 2026

Key Highlights

The Latest Trading Price of Global Longlife Hospital and Research Ltd is ₹ 12.57 as of 23 Oct 15:30 . The P/E Ratio of Global Longlife Hospital and Research Ltd changed from 0 on March 2023 to 0 on March 2026 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 years The Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore on March 2023 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 years The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 8 quarters. This represents a CAGR of 34.06% The Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution that offer to every human being, high quality healthcare at affordable prices in Ahmedabad. Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

FAQs for the comparison of Global Longlife Hospital and Research Ltd and Gujarat Kidney & Super Speciality Ltd

Which company has a larger market capitalization, Global Longlife Hospital and Research Ltd or Gujarat Kidney & Super Speciality Ltd?

Market cap of Global Longlife Hospital and Research Ltd is 13 Cr while Market cap of Gujarat Kidney & Super Speciality Ltd is 1,395 Cr

What are the key factors driving the stock performance of Global Longlife Hospital and Research Ltd and Gujarat Kidney & Super Speciality Ltd?

The stock performance of Global Longlife Hospital and Research Ltd and Gujarat Kidney & Super Speciality Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Global Longlife Hospital and Research Ltd and Gujarat Kidney & Super Speciality Ltd?

As of October 24, 2026, the Global Longlife Hospital and Research Ltd stock price is INR ₹12.57. On the other hand, Gujarat Kidney & Super Speciality Ltd stock price is INR ₹176.95.

How do dividend payouts of Global Longlife Hospital and Research Ltd and Gujarat Kidney & Super Speciality Ltd compare?

To compare the dividend payouts of Global Longlife Hospital and Research Ltd and Gujarat Kidney & Super Speciality Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.